Pharmaceutics Technology Offers

Covid-19 Innovation Challenges by Innoget posted this:

Expertise in molecular biology either experimentally or computationally The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Expertise in molecular biology either experimentally or computationally

TEC Edmonton posted this:

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

Covid-19 Innovation Challenges by Innoget posted this:

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

Antibacterial alternative to antibiotics, with high specificity against Escherichia coli The "Molecular Microbiology" research group at the University of Alicante has modified several phage proteins (Poll-N and UK-C) that have high specificity against Escherichia coli (E. coli), but not against other Gram-negative (G-) bacteria. For these reasons, their use as a specific antimicrobial against E. coli is potentially interesting, especially in the case of contaminated food, cosmetics or water. It would also be useful in the treatment of diseases (infections) caused by E. coli. The presence of a histidine tail attached to the phage proteins not only facilitates their purification but also improves lysis efficiency without the need of cell permeabilization treatments. Companies interested in the commercial exploitation of the technology through license agreements and/or technical cooperation are sought.

Antibacterial alternative to antibiotics, with high specificity against Escherichia coli

University of Vigo posted this:

Procedure for the extraction of biosurfactants contained in corn steep liquors Nowadays, most of the pharmaceutical and cosmetic products in the market contain chemically synthesized surfactants in its composition. In many cases, these surfactants are the same as those used in regular cleanup activities. In order to get more natural and biocompatible products, it would be interesting to include natural surfactants instead of chemical surfactants in the preparation of these pharmaceutical and cosmetic products. These biosurfactants are also present in the formulation of greener nanoparticles, replacing the chemical surfactants currently used in the preparation thereof. Most biosurfactants have antimicrobial activity, which would improve the properties of certain nanoparticles, as well as many pharmaceutical and cosmetic products. The main disadvantage of biosurfactants industrial production is related to the high cost compared to chemically synthesized surfactant production. The solution proposed by the Chemical Engineering research group at the University of Vigo, is the development of eco-friendly simple extraction of biosurfactant from a corn wet-milling industry byproduct, such as corn wash liquors, better known as "corn steep liquor (CSL)", which could compete in terms of cost production with its chemical counterparts.

UACOOPERA University of Aveiro posted this:
Technology Transfer Office at uacoopera

Immunoglobulin Y Purification, Its Products And Uses This invention describes a purification process of immunoglobulin Y from egg yolk in three stages, by applying precipitation methods, liquid-liquid extraction and ultracentrifugation. The present process allows to obtain immunoglobulin Y of high quality and with a purity >95%, in a simple and economic way, and applicable at an industrial scale.

Immunoglobulin Y Purification, Its Products And Uses

Consejo Superior de Investigaciones Científicas posted this:

Immunoassay for rapid diagnosis of infectious diseases caused by Pseudomonas aeruginosa CSIC, CIBER-BBN and UAB have developed an immunochemical method for diagnosis of infections produced by Pseudomonas aeruginosa. The immunoassay is fast and efficient, with low LOD and adaptable to point-of care devices.

Immunoassay for rapid diagnosis of infectious diseases caused by Pseudomonas

Consejo Superior de Investigaciones Científicas posted this:

Biocatalysts for the food, pharmaceutical and cosmetic industry made from used batteries The CSIC has developed a system that use the black mass of the used batteries to synthesize biocatalysts with a great capacity to synthesize products widely used in the food, pharmaceutical and cosmetic industry, such as aromas and flavorings. Companies interested in exploiting the technology under a patent license are sought. An offer for Patent Licensing

Biocatalysts for the food, pharmaceutical and cosmetic industry made from used batteries

Consejo Superior de Investigaciones Científicas posted this:

New antioxidant compounds: Polyphenols amide derivatives CSIC has synthetized and studied unknown polyphenolic compounds possessing high antioxidant activity, comparable and in some cases even higher than those of known natural polyphenols, as resveratrol and hydroxytyrosol. We are seeking for Pharmaceutical, Biotechnological, Food or Cosmetics companies interested in developing and marketing these compounds as drugs, cosmetics ingredients or dietary supplements under patent licensing. An offer for Patent Licensing

New antioxidant compounds: Polyphenols amide derivatives

Consejo Superior de Investigaciones Científicas posted this:

Oleuropein obtaining procedure: high purity antioxidant CSIC has developed a reliable and effective method for obtaining oleuropein from olive leaf: comprising a pretreatment that increases the concentration of oleuropein in the extracts over other known methods and achieving this bioactive compound with a purity superior of 70%. Industrial partners from the food and pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Oleuropein obtaining procedure: high purity antioxidant

Consejo Superior de Investigaciones Científicas posted this:

Myt-healer: a new potent wound healing peptide CSIC and the University Miguel Hernández have developed a minimal peptide core from the M yti lus galloprovidencialis Myticin C peptide with unique in vitro and in vivo wound healing and regenerating activities. Industrial partners from the pharmaceutical and cosmetic industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Myt-healer: a new potent wound healing peptide

Consejo Superior de Investigaciones Científicas posted this:

OPTOBIOTICS: Novel antibacterial proteins activated by blue light CSIC has developed a chimeric protein that, when expressed in bacteria, changes its structure upon absorption of blue light, thus generating protein aggregates (amyloids) that inhibit bacterial growth Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement An offer for Patent Licensing

OPTOBIOTICS: Novel antibacterial proteins activated by blue light

Otava Research Institute posted this:

Computer aided drug discovery services Otava Research Institute helps researchers around the world develop advanced solutions for the variety of research projects maximizing their efficiencies, and, most of all, respecting their budgets. Our experts are involved in the development of leading compounds at any stage of the R&D process: starting from target identification to lead optimization

Computer aided drug discovery services

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

Ultrasonic capillary reactor with temperature control and homogeneous vibration The Photochemistry and Semiconductor Electrochemistry (GFES) research group of the University of Alicante has developed an ultrasonically-enhanced capillary reactor which achieves homogeneous, efficient and temperature-controlled multiphase flow. The reactor features a capillary tube in a helicoidal probe that homogenizes the acoustic field generated without the appearance of longitudinal nodes and antinodes. Continuous and/or oscillatory reactions including crystallization phenomena are enabled, allowing the handling of solids and/or the improvement of heterogeneous mixtures in capillary tubes of variable diameter and length with optimum temperature control. Therefore, this reactor provides an advantage in flow chemistry and process intensification which is common in the pharmaceutical industry, fine chemistry, and in sonochemistry. The invention is protected by a patent application. The research group has a prototype on a laboratory scale. Companies interested in the commercial exploitation of this technology are sought through patent licensing agreements or technical cooperation agreements (R&D Projects).

Ultrasonic capillary reactor with temperature control and homogeneous vibration

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

New multifunctional material for controlled-drug-release implants The "Advanced Materials" research group at the University of Alicante has developed a foamed material comprising three phases: a structural matrix, at least one host phase, and a fluid. This material is characterized by the fact that the structural matrix comprises a plurality of interconnected porous cavities, the host phase(s) is/are housed within at least one porous cavity of the structural matrix and the fluid is housed within the porous cavities. The host phase(s) can be housed within the porous cavities of the structural matrix without maintaining any union or maintaining discrete unions with the latter. The structural matrix may consist of a material of a metallic, polymeric, ceramic nature or mixtures thereof. Meanwhile, the host phase(s) is/are a functional material, the fluid being a liquid or a gas. These materials have many potential uses, among which ones is as an implant material, with the additional possibility of exerting a controlled release of drugs. Companies interested in commercial exploitation of this material through a patent license agreement are sought.

New multifunctional material for controlled-drug-release implants

1
2
3
4